Jiejie Xu

List of Publications by Year in Descending Order

148 papers	2,447 citations	24 h-index	41 g-index
157 ext. papers	3,183 ext. citations	4.9 avg, IF	4.94 L-index

#	Paper	IF	Citations
148	ASO Visual Abstract: Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients.. *Annals of Surgical Oncology*, **2022**, 29, 2504	3.1	
147	Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.. *Cancer Immunology, Immunotherapy*, **2022**, 1	7.4	
146	Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients.. *Annals of Surgical Oncology*, **2022**, 1	3.1	0
145	CD103CD8 tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer.. *British Journal of Cancer*, **2022**,	8.7	1
144	Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer. *Cancer Immunology, Immunotherapy*, **2021**, 1	7.4	0
143	ASO Author Reflections: Optimization of Tumor Therapy for the Specific Immune Microenvironment of Gastric Cancer. *Annals of Surgical Oncology*, **2021**, 28, 6451-6452	3.1	
142	Intratumoral CXCR5CD8T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer. *Nature Communications*, **2021**, 12, 3080	17.4	4
141	Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis. *Cancer Immunology, Immunotherapy*, **2021**, 1	7.4	1
140	Blocking siglec-10 tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma. *Experimental Hematology and Oncology*, **2021**, 10, 36	7.8	7
139	Lymphocyte-activation gene 3 expression associates with poor prognosis and immunoevasive contexture in Epstein-Barr virus-positive and MLH1-defective gastric cancer patients. *International Journal of Cancer*, **2021**, 148, 759-768	7.5	4
138	Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. *OncoImmunology*, **2021**, 10, 1915560	7.2	4
137	Intratumoral CXCL13CD8T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma **2021**, 9,		20
136	Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients. *Annals of Surgical Oncology*, **2021**, 28, 6439-6450	3.1	3
135	Poor clinical outcomes and immunoevasive contexture in SIRP□tumor-associated macrophages enriched muscle-invasive bladder cancer patients. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 40, 109.e11-109.e11	2.8	0
134	Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer. *European Journal of Cancer*, **2021**, 157, 114-123	7.5	3
133	Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer. *OncoImmunology*, **2021**, 10, 1975386	7.2	2
132	CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer. *Cancer Immunology, Immunotherapy*, **2020**, 69, 1855-1867	7.4	11

131	CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma **2020**, 8,		4
130	Stromal LAG-3 cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture **2020**, 8,		13
129	Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8 T cells in gastric cancer. *Cancer Immunology, Immunotherapy*, **2020**, 69, 1327-1336	7.4	13
128	Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103CD8 T cells conferring favourable prognosis. *British Journal of Cancer*, **2020**, 122, 1525-1534	8.7	15
127	Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer. *European Journal of Cancer*, **2020**, 128, 27-37	7.5	12
126	Blockade of DC-SIGN Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer. *Cancer Research*, **2020**, 80, 1707-1719	10.1	27
125	Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients **2020**, 8,		17
124	Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin cell abundance. *OncoImmunology*, **2020**, 9, 1747333	7.2	9
123	Latency-associated Peptide Identifies Immunoevasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness. *Annals of Surgery*, **2020**, 275,	7.8	6
122	Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses. *International Journal of Cancer*, **2020**, 146, 542-552	7.5	7
121	PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 293-304	2.8	5
120	Tumor-infiltrating podoplanin cells in gastric cancer: clinical outcomes and association with immune contexture. *OncoImmunology*, **2020**, 9, 1845038	7.2	1
119	Tumor-infiltrating TNFRSF9 CD8 T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response. *OncoImmunology*, **2020**, 9, 1838141	7.2	8
118	Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer. *International Journal of Cancer*, **2020**, 147, 3539-3549	7.5	3
117	Intratumoral CCR5 neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses. *OncoImmunology*, **2020**, 9, 1802176	7.2	2
116	Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 41.e11-41.e18	2.8	8
115	Tumor-infiltrating CD39CD8 T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients. *Cancer Immunology, Immunotherapy*, **2020**, 69, 1565-1576	7.4	38
114	Tumor-infiltrating IL-17A cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer. *OncoImmunology*, **2020**, 9, 1747332	7.2	4

113	Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. *Gut*, **2019**, 68, 1764-1773	19.2	118
112	Failure to Cite Related Studies and Report Complete Information on Patients and Tissue Samples. *JAMA Surgery*, **2019**, 154, 362-363	5.4	0
111	Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response. *Cancer Immunology, Immunotherapy*, **2019**, 68, 2067-2080	7.4	20
110	Tumor infiltrating mast cells determine oncogenic HIF-2α conferred immune evasion in clear cell renal cell carcinoma. *Cancer Immunology, Immunotherapy*, **2019**, 68, 731-741	7.4	21
109	Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. *OncoImmunology*, **2019**, 8, e1515611	7.2	3
108	CD19 tumor-infiltrating B-cells prime CD4 T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer. *Cancer Immunology, Immunotherapy*, **2019**, 68, 45-56	7.4	22
107	Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. *European Urology*, **2019**, 75, 752-763	10.2	61
106	Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. *Clinical Cancer Research*, **2018**, 24, 3069-3078	12.9	83
105	CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 242.e15-242.e21	2.8	2
104	Evaluation of Tumor Pseudocapsule Status and its Prognostic Significance in Renal Cell Carcinoma. *Journal of Urology*, **2018**, 199, 915-920	2.5	10
103	Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients. *BMC Cancer*, **2018**, 18, 313	4.8	6
102	C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. *OncoImmunology*, **2018**, 7, e1433517	7.2	13
101	CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. *Cancer Immunology, Immunotherapy*, **2018**, 67, 261-269	7.4	28
100	HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients. *Cancer Immunology, Immunotherapy*, **2018**, 67, 79-87	7.4	5
99	B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients. *BMC Cancer*, **2018**, 18, 590	4.8	9
98	Tumor infiltrating CD19 B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. *OncoImmunology*, **2018**, 7, e1477461	7.2	86
97	Prognostic significance of ST6GalNAc-1 expression in patients with non-metastatic clear cell renal cell carcinoma. *Oncotarget*, **2018**, 9, 3112-3120	3.3	3
96	Tumor-infiltrating Neutrophils is Prognostic and Predictive for Postoperative Adjuvant Chemotherapy Benefit in Patients With Gastric Cancer. *Annals of Surgery*, **2018**, 267, 311-318	7.8	98

95	Prognostic and Predictive Value of O-methylguanine Methyltransferase for Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. *Annals of Surgical Oncology*, **2018**, 25, 342-348	3.1	3
94	Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer. *OncoImmunology*, **2018**, 7, e1474317	7.2	39
93	Tumor-infiltrating neutrophils predict prognosis and adjuvant chemotherapeutic benefit in patients with biliary cancer. *Cancer Science*, **2018**, 109, 2266-2274	6.9	17
92	Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. *OncoImmunology*, **2017**, 6, e1293211	7.2	37
91	Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. *BMC Cancer*, **2017**, 17, 117	4.8	5
90	Beta-1,4-galactosyltransferase II predicts poor prognosis of patients with non-metastatic clear-cell renal cell carcinoma. *Tumor Biology*, **2017**, 39, 1010428317691417	2.9	3
89	Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 349-355	2.8	19
88	Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma. *Annals of Surgical Oncology*, **2017**, 24, 1435-1442	3.1	24
87	Enhancement of Siglec-8 expression predicts adverse prognosis in patients with clear cell renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 607.e1-607.e8	2.8	3
86	Decreased expression of granulocyte-macrophage colony-stimulating factor is associated with adverse clinical outcome in patients with gastric cancer undergoing gastrectomy. *Oncology Letters*, **2017**, 14, 4701-4707	2.6	0
85	High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma. *Oncotarget*, **2017**, 8, 7548-7558	3.3	7
84	High expression of CXC chemokine receptor 6 associates with poor prognosis in patients with clear cell renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 675.e17-675.e24	2.8	9
83	Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer. *JAMA Surgery*, **2017**, 152, e173120	5.4	14
82	Tumor-infiltrating Ⅱ cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer. *OncoImmunology*, **2017**, 6, e1353858	7.2	19
81	Decreased expression of JMJD3 predicts poor prognosis of patients with clear cell renal cell carcinoma. *Oncology Letters*, **2017**, 14, 1550-1560	2.6	7
80	High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients. *OncoImmunology*, **2017**, 6, e1359450	7.2	5
79	Prognostic value of copper transporter 1 expression in patients with clear cell renal cell carcinoma. *Oncology Letters*, **2017**, 14, 5791-5800	2.6	6
78	Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. *BMC Cancer*, **2017**, 17, 70	4.8	10

77	CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients. *Oncotarget*, **2017**, 8, 20328-20339	3.3	10
76	Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma. *Oncotarget*, **2017**, 8, 25650-25659	3.3	5
75	High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients. *Oncotarget*, **2017**, 8, 35244-35254	3.3	7
74	Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma. *Oncotarget*, **2017**, 8, 14995-15003	3.3	3
73	High mucin 5AC expression predicts adverse postoperative recurrence and survival of patients with clear-cell renal cell carcinoma. *Oncotarget*, **2017**, 8, 59777-59790	3.3	8
72	High expression of FUT3 is linked to poor prognosis in clear cell renal cell carcinoma. *Oncotarget*, **2017**, 8, 61036-61047	3.3	5
71	IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma. *Oncotarget*, **2017**, 8, 44186-44194	3.3	2
70	Prognostic value of granulocyte colony-stimulating factor in patients with non-metastatic clear cell renal cell carcinoma. *Oncotarget*, **2017**, 8, 69961-69971	3.3	7
69	Stathmin 1 expression predicts prognosis and benefits from adjuvant chemotherapy in patients with gallbladder carcinoma. *Oncotarget*, **2017**, 8, 108548-108555	3.3	5
68	High truncated-O-glycan score predicts adverse clinical outcome in patients with localized clear-cell renal cell carcinoma after surgery. *Oncotarget*, **2017**, 8, 80083-80092	3.3	
67	An indel polymorphism within pre-miR3131 confers risk for hepatocellular carcinoma. *Carcinogenesis*, **2017**, 38, 168-176	4.6	9
66	High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma. *Annals of Surgical Oncology*, **2016**, 23, 1044-52	3.1	8
65	Increased expression of C-C motif ligand 2 associates with poor prognosis in patients with gastric cancer after gastrectomy. *Tumor Biology*, **2016**, 37, 3285-93	2.9	8
64	Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. *BJU International*, **2016**, 117, 351-62	5.6	64
63	Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. *Journal of Urology*, **2016**, 196, 1363-1370	2.5	30
62	High Level of Anaphylatoxin C5a Predicts Poor Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma. *Scientific Reports*, **2016**, 6, 29177	4.9	12
61	Dectin-1 predicts adverse postoperative prognosis of patients with clear cell renal cell carcinoma. *Scientific Reports*, **2016**, 6, 32657	4.9	5
60	The Presence of Vascular Mimicry Predicts High Risk of Clear Cell Renal Cell Carcinoma after Radical Nephrectomy. *Journal of Urology*, **2016**, 196, 335-42	2.5	4

59	Decreased expression of Siglec-8 associates with poor prognosis in patients with gastric cancer after surgical resection. *Tumor Biology*, **2016**, 37, 10883-91	2.9	9
58	High expression of chemokine CCL2 is associated with recurrence after surgery in clear-cell renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 238.e19-26	2.8	11
57	Decreased expression of CTR2 predicts poor prognosis of patients with clear cell renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 5.e1-9	2.8	5
56	IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma. *Tumor Biology*, **2016**, 37, 11127-34	2.9	11
55	Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. *Tumor Biology*, **2016**, 37, 4523-9	2.9	8
54	Prognostic value of preoperative lymphocyte to monocyte ratio in patients with nonmetastatic clear cell renal cell carcinoma. *Tumor Biology*, **2016**, 37, 4613-20	2.9	16
53	Interleukin-13 receptor 2 is associated with poor prognosis in patients with gastric cancer after gastrectomy. *Oncotarget*, **2016**, 7, 49281-49288	3.3	14
52	CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma. *Oncotarget*, **2016**, 7, 51525-51534	3.3	23
51	High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. *Oncotarget*, **2016**, 7, 63661-63668	3.3	7
50	A three-molecule score based on Notch pathway predicts poor prognosis in non-metastasis clear cell renal cell carcinoma. *Oncotarget*, **2016**, 7, 68559-68570	3.3	5
49	Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma. *Oncotarget*, **2016**, 7, 84775-84784	3.3	7
48	Prognostic value of vascular mimicry in patients with urothelial carcinoma of the bladder after radical cystectomy. *Oncotarget*, **2016**, 7, 76214-76223	3.3	3
47	Enrichment of C5a-C5aR axis predicts poor postoperative prognosis of patients with clear cell renal cell carcinoma. *Oncotarget*, **2016**, 7, 80925-80934	3.3	16
46	Positive intratumoral chemokine (C-C motif) receptor 8 expression predicts high recurrence risk of post-operation clear-cell renal cell carcinoma patients. *Oncotarget*, **2016**, 7, 8413-21	3.3	5
45	Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma. *Oncotarget*, **2016**, 7, 13976-83	3.3	19
44	High expression of C-C chemokine receptor 2 associates with poor overall survival in gastric cancer patients after surgical resection. *Oncotarget*, **2016**, 7, 23909-18	3.3	7
43	Granulocyte macrophage colony-stimulating factor predicts postoperative recurrence of clear-cell renal cell carcinoma. *Oncotarget*, **2016**, 7, 24527-36	3.3	6
42	Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma. *Oncotarget*, **2016**, 7, 32723-30	3.3	17

41	High expression of galectin-7 associates with poor overall survival in patients with non-metastatic clear-cell renal cell carcinoma. *Oncotarget*, **2016**, 7, 41986-41995	3.3	4
40	Increased expression of MUC3A is associated with poor prognosis in localized clear-cell renal cell carcinoma. *Oncotarget*, **2016**, 7, 50017-50026	3.3	12
39	Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. *Scientific Reports*, **2016**, 6, 21319	4.9	50
38	Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer. *Scientific Reports*, **2016**, 6, 38364	4.9	4
37	Podoplanin associates with adverse postoperative prognosis of patients with clear cell renal cell carcinoma. *Cancer Science*, **2016**, 107, 1243-9	6.9	3
36	Prognostic value of UTX expression in patients with clear cell renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 338.e19-27	2.8	5
35	High mucin-7 expression is an independent predictor of adverse clinical outcomes in patients with clear-cell renal cell carcinoma. *Tumor Biology*, **2016**, 37, 15193-15201	2.9	10
34	Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery. *Tumor Biology*, **2016**, 37, 12635-12642	2.9	12
33	1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. *World Journal of Urology*, **2015**, 33, 1791-9	4	9
32	p21-activated kinase 1 predicts recurrence and survival in patients with non-metastatic clear cell renal cell carcinoma. *International Journal of Urology*, **2015**, 22, 447-53	2.3	5
31	High APOBEC3B expression is a predictor of recurrence in patients with low-risk clear cell renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 340.e1-8	2.8	27
30	p21-Activated kinase 4 predicts early recurrence and poor survival in patients with nonmetastatic clear cell renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 205.e13-21	2.8	6
29	Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma. *Carcinogenesis*, **2015**, 36, 1136-43	4.6	90
28	Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma. *Japanese Journal of Clinical Oncology*, **2015**, 45, 202-9	2.8	15
27	Galectin-8 predicts postoperative recurrence of patients with localized T1 clear cell renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 112.e1-8	2.8	5
26	Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma. *BMC Cancer*, **2015**, 15, 67	4.8	22
25	Snail predicts recurrence and survival of patients with localized clear cell renal cell carcinoma after surgical resection. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 69.e1-10	2.8	12
24	Clinical significance of tumor-derived IL-1 and IL-18 in localized renal cell carcinoma: Associations with recurrence and survival. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 68.e9-16	2.8	28

23	EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. *Nature Communications*, **2015**, 6, 8494	17.4	79
22	Tumor Suppressive Function of p21-activated Kinase 6 in Hepatocellular Carcinoma. *Journal of Biological Chemistry*, **2015**, 290, 28489-28501	5.4	14
21	CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma. *European Journal of Cancer*, **2015**, 51, 1953-61	7.5	23
20	Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. *Gastric Cancer*, **2015**, 18, 740-50	7.6	100
19	High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. *Cancer Science*, **2015**, 106, 592-7	6.9	19
18	P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma. *Cancer Science*, **2015**, 106, 1224-31	6.9	23
17	High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma. *Scientific Reports*, **2015**, 5, 16954	4.9	33
16	The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients. *BMC Cancer*, **2015**, 15, 766	4.8	22
15	Prognostic significance of ST3GAL-1 expression in patients with clear cell renal cell carcinoma. *BMC Cancer*, **2015**, 15, 880	4.8	13
14	High peritumoral Bmi-1 expression is an independent prognosticator of poor prognosis in renal cell carcinoma. *Tumor Biology*, **2015**, 36, 8007-14	2.9	3
13	Prognostic significance of β1,6-N-acetylglucosaminyltransferase V expression in patients with hepatocellular carcinoma. *Japanese Journal of Clinical Oncology*, **2015**, 45, 844-53	2.8	11
12	Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis. *British Journal of Cancer*, **2015**, 113, 1581-9	8.7	22
11	Notch1 predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. *Urology*, **2015**, 85, 483.e9-483.e14	1.6	6
10	Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma. *International Journal of Clinical and Experimental Pathology*, **2015**, 8, 1594-603	1.4	14
9	Decreased expression of mucin 18 is associated with unfavorable postoperative prognosis in patients with clear cell renal cell carcinoma. *International Journal of Clinical and Experimental Pathology*, **2015**, 8, 11005-14	1.4	6
8	Expression of Jagged1 predicts postoperative clinical outcome of patients with gastric cancer. *International Journal of Clinical and Experimental Medicine*, **2015**, 8, 14782-92		3
7	Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. *Annals of Surgical Oncology*, **2014**, 21, 3142-50	3.1	80
6	Discovery of specific metastasis-related N-glycan alterations in epithelial ovarian cancer based on quantitative glycomics. *PLoS ONE*, **2014**, 9, e87978	3.7	35

5	GALNT4 predicts clinical outcome in patients with clear cell renal cell carcinoma. *Journal of Urology*, **2014**, 192, 1534-41	2.5	10
4	Functional short tandem repeat polymorphism of PTPN11 and susceptibility to hepatocellular carcinoma in Chinese populations. *PLoS ONE*, **2014**, 9, e106841	3.7	6
3	Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1. *Gastroenterology*, **2012**, 143, 199-212.e4	13.3	60
2	Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. *Cancer Research*, **2011**, 71, 7547-57	10.1	70
1	Identification of beta-1,4-galactosyltransferase I as a target gene of HBx-induced cell cycle progression of hepatoma cell. *Journal of Hepatology*, **2008**, 49, 1029-37	13.4	25